IMR Press / FBL / Volume 17 / Issue 6 / DOI: 10.2741/4055

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Endothelial progenitor cells in atherosclerosis
Show Less
1 Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA
2 Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA, 1914
3 Thrombosis Research Center of Temple University School of Medicine, Philadelphia, PA, 19140

Academic Editor: Xiao-Feng Yang

Front. Biosci. (Landmark Ed) 2012, 17(6), 2327–2349;
Published: 1 June 2012
(This article belongs to the Special Issue Amylin in vasodilation, energy expenditure and inflammation)

Endothelial progenitor cells (EPCs) are involved in the maintenance of endothelial homoeostasis and in the process of new vessel formation. Experimental and clinical studies have shown that atherosclerosis is associated with reduced numbers and dysfunction of EPCs; and that medications alone are able to partially reverse the impairment of EPCs in patients with atherosclerosis. Therefore, novel EPC-based therapies may provide enhancement in restoring EPCs' population and improvement of vascular function. Here, for a better understanding of the molecular mechanisms underlying EPC impairment in atherosclerosis, we provide a comprehensive overview on EPC characteristics, phenotypes, and the signaling pathways underlying EPC impairment in atherosclerosis.

Back to top